WO2007143104A8 - Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations - Google Patents
Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisationsInfo
- Publication number
- WO2007143104A8 WO2007143104A8 PCT/US2007/012958 US2007012958W WO2007143104A8 WO 2007143104 A8 WO2007143104 A8 WO 2007143104A8 US 2007012958 W US2007012958 W US 2007012958W WO 2007143104 A8 WO2007143104 A8 WO 2007143104A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- production
- methods
- cell receptor
- receptor mimics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002656583A CA2656583A1 (fr) | 2006-06-01 | 2007-06-01 | Anticorps utiles en tant qu'analogues de recepteur des lymphocytes t, leurs procedes de production et leurs utilisations |
EP07777355A EP2026837A4 (fr) | 2006-06-01 | 2007-06-01 | Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations |
AU2007254859A AU2007254859A1 (en) | 2006-06-01 | 2007-06-01 | Antibodies as T cell receptor mimics, methods of production and uses thereof |
IL195470A IL195470A0 (en) | 2006-06-01 | 2008-11-24 | Antibodies as t cell receptor mimics, methods of production and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81007906P | 2006-06-01 | 2006-06-01 | |
US60/810,079 | 2006-06-01 | ||
US11/517,516 | 2006-09-07 | ||
US11/517,516 US20070092530A1 (en) | 2004-05-27 | 2006-09-07 | Antibodies as T cell receptor mimics, methods of production and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007143104A2 WO2007143104A2 (fr) | 2007-12-13 |
WO2007143104A8 true WO2007143104A8 (fr) | 2008-07-31 |
Family
ID=40262722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/012958 WO2007143104A2 (fr) | 2006-06-01 | 2007-06-01 | Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2026837A4 (fr) |
AU (1) | AU2007254859A1 (fr) |
CA (1) | CA2656583A1 (fr) |
IL (1) | IL195470A0 (fr) |
WO (1) | WO2007143104A2 (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108372A2 (fr) * | 2008-02-27 | 2009-09-03 | Receptor Logic, Inc. | Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d’utilisation |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
IL295398A (en) | 2015-10-23 | 2022-10-01 | Eureka Therapeutics Inc | Antibody/t-cell receptor chimera structures and their uses |
GB201520597D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520567D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
GB201520562D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201604468D0 (en) | 2016-03-16 | 2016-04-27 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520558D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520539D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520595D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520557D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520541D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520589D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
WO2017089786A1 (fr) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
GB201520579D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520575D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520548D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520563D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520542D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520565D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520544D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520603D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520543D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520570D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520536D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201607535D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520564D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520559D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520546D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520545D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520566D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
CA3025894A1 (fr) | 2016-06-02 | 2017-12-07 | Immunocore Limited | Schema de traitement pour proteine de fusion scfv tcr-anti-cd3 gp100 specifique |
US20210115099A1 (en) | 2016-11-07 | 2021-04-22 | Immunocore Limited | Peptides |
SG10201913656TA (en) | 2017-04-26 | 2020-03-30 | Eureka Therapeutics Inc | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
AU2017418590A1 (en) | 2017-06-14 | 2020-01-16 | Adicet Therapeutics, Inc. | Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof |
GB201815041D0 (en) | 2018-09-14 | 2018-10-31 | Scancell Ltd | Epitopes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541429B2 (en) * | 2000-10-10 | 2009-06-02 | The Board Of Regents Of The University Of Oklahoma | Comparative ligand mapping from MHC positive cells |
US20050003483A1 (en) * | 2000-10-10 | 2005-01-06 | Hildebrand William H. | Comparative ligand mapping from MHC class 1 positive cells |
EP1485075A4 (fr) * | 2002-02-20 | 2006-04-26 | Dyax Corp | Ligands de liaison au complexe mhc-peptide |
US20070105779A1 (en) * | 2002-07-31 | 2007-05-10 | Danila Valmori | Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof |
CA2567814C (fr) * | 2004-05-27 | 2013-07-23 | Jon A. Weidanz | Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation |
CA2662798A1 (fr) * | 2005-09-07 | 2007-03-15 | Receptor Logic, Ltd. | Anticorps utilises comme mimetiques de recepteurs de lymphocytes t, leurs methodes de production et leurs applications |
-
2007
- 2007-06-01 WO PCT/US2007/012958 patent/WO2007143104A2/fr active Application Filing
- 2007-06-01 AU AU2007254859A patent/AU2007254859A1/en not_active Abandoned
- 2007-06-01 CA CA002656583A patent/CA2656583A1/fr not_active Abandoned
- 2007-06-01 EP EP07777355A patent/EP2026837A4/fr not_active Withdrawn
-
2008
- 2008-11-24 IL IL195470A patent/IL195470A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL195470A0 (en) | 2011-08-01 |
CA2656583A1 (fr) | 2007-12-13 |
EP2026837A2 (fr) | 2009-02-25 |
WO2007143104A2 (fr) | 2007-12-13 |
EP2026837A4 (fr) | 2010-06-02 |
AU2007254859A1 (en) | 2007-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007143104A8 (fr) | Anticorps utiles en tant qu'analogues de récepteur des lymphocytes t, leurs procédés de production et leurs utilisations | |
IL179427A0 (en) | Antibodies as t cell receptor mimics, methods of production and uses thereof | |
EP2343362B8 (fr) | Procédé pour améliorer la culture cellulaire | |
EP2436696B8 (fr) | Anticorps anti-amyloide et son utilisation | |
EP1988152A4 (fr) | Construction pour la culture cellulaire, contenant pour la culture cellulaire, construction ayant un sphéroïde, contenant ayant un sphéroïde et procédé de production correspondant | |
EP3121266B8 (fr) | Milieux de culture cellulaire sans oligopeptides | |
EP1857126A4 (fr) | Feuille de cellules cultivees, son procede de production et son procede d application | |
IL190472A (en) | Glyphican Antibody 3 Methods for their preparation and use | |
EP2068389B8 (fr) | Procédé de production d'un séparateur pour pile à combustible, séparateur pour pile à combustible et pile a combustible | |
WO2008002893A8 (fr) | Anticorps anti-amyloïdes, compositions, procédés et utilisations | |
WO2008063675A3 (fr) | Cellules progénitrices endothermiques | |
WO2009102569A3 (fr) | Nouvelles lignées cellulaires et méthodes associées | |
WO2009006359A8 (fr) | Anticorps anti-mcp-1, compositions, procédés et utilisations | |
AU2009213453A8 (en) | Anti-ADAM-15 antibodies and utilization of the same | |
EP2262834A4 (fr) | Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d utilisation | |
IL190014A0 (en) | Antibodies as t cell receptor mimics, methods of production and uses thereof | |
EP2017913A4 (fr) | Diaphragme pour pile à combustible liquide directe et son procédé de fabrication | |
EP2005163B8 (fr) | Procédé relatif à des essais à base de cellules | |
EP2252448A4 (fr) | Cellules à colorant de grande surface, et leurs procédés de fabrication | |
AU2007905553A0 (en) | Process for the production of P2X7 antibodies and their use | |
AU2007904460A0 (en) | Method of proliferating cells | |
AU2006901495A0 (en) | Cell culture | |
AU2006903659A0 (en) | Antibodies and related methods | |
AU2014201623B2 (en) | Pluripotent stem cell culture | |
AU2006906788A0 (en) | Production of biofuels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07777355 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007254859 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2656583 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007777355 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: 2007254859 Country of ref document: AU Date of ref document: 20070601 Kind code of ref document: A |